Keele Research Repository

Article

Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Burden, AD, Barker, JNWN, Lunt, M, Ali, H, Kleyn, CE, McElhone, K, Soliman, MM, Green, AC, Griffiths, CEM, Reynolds, NJ and Ormerod, AD (2021) Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non‐biologic systemic therapies. Journal of the European Academy of Dermatology and Venereology.

Rungapiromnan, W, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Lunt, M, McElhone, K, Rutter, MK, Warren, RB, Griffiths, CEM, Ashcroft, DM and Grp, BADBIRS (2019) Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR). Pharmacoepidemiology and Drug Safety, 27. 467 - 467.

Rungapiromnan, W, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Lunt, M, McElhone, K, Burden, AD, Rutter, MK, Warren, RB, Griffiths, CEM, Ashcroft, DM and Study Group, BADBIR (2019) Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. Journal of the European Academy of Dermatology and Venereology, 34 (4). 769 - 778.

Yiu, ZZN, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Barker, JNWN, Hampton, PJ, McElhone, K, Smith, CH, Warren, RB, Griffiths, CEM, Lunt, M, Burden, AD and Study Group, BADBIR (2019) A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. British Journal of Dermatology, 181 (6). 1265 - 1271.

Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Williams, S, Yiu, ZZN, McElhone, K, Ashcroft, DM, Kleyn, CE, Jabbar-Lopez, ZK, Owen, CM, Reynolds, NJ, Smith, CH, Wilson, N, Warren, RB and Griffiths, CEM (2019) Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. British Journal of Dermatology, 181 (2). 256 - 264.

Yiu, ZZN, Ashcroft, DM, Evans, I, McElhone, K ORCID: https://orcid.org/0000-0002-5419-0669, Lunt, M, Smith, CH, Walton, S, Murphy, R, Reynolds, NJ, Ormerod, AD, Griffiths, CEM, Warren, RB and Study Group, BADBIR (2018) Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). British Journal of Dermatology, 180 (2). 329 - 337.

Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Barker, JNWN, Smith, CH, Hampton, PJ, Lunt, M, McElhone, K, Warren, RB, Yiu, ZZN, Griffiths, CEM, Burden, AD and Study Group, BADBIR (2018) Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. JAMA Dermatology, 154 (5). 581 - 588.

Iskandar, IYK, Warren, RB, Lunt, M, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Evans, I, McElhone, K, Smith, CH, Reynolds, NJ, Ashcroft, DM, Griffiths, CEM and Study Group, BADBIR (2017) Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 138 (4). 775 - 784.